Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9

Benzinga Newsdesk www.benzinga.com Positive 87.6%

Neg 0% Neu 0% Pos 87.6%

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $8.25 to $9.